Coronavirus Disease 2019 and Liver Transplantation: Lessons from the First Year of the Pandemic

Meaghan M. Phipps, Elizabeth C. Verna – 4 June 2021 – Over the last year, the novel coronavirus disease 2019 (COVID‐19) has continued to spread across the globe, causing significant morbidity and mortality among transplantation candidates and recipients. Patients with end‐stage liver disease awaiting liver transplantation and patients with a history of liver transplantation represent vulnerable populations, especially given the high rates of associated medical comorbidities in these groups and their immunosuppressed status.

The Impact of Primary Liver Disease and Social Determinants in a Mixed Donor Liver Transplant Program: A Single‐Center Analysis

Kristel K. Leung, Audrey Kim, Bettina E. Hansen, Les Lilly, Nazia Selzner, Keyur Patel, Mamatha Bhat, Gideon M. Hirschfield, Zita Galvin – 4 June 2021 – Organ allocation in liver transplantation (LT) remains imperfect. Periodic center reviews ensure programs transparently evaluate the impact of practice on access to transplantation, reflecting, in particular, patient (primary disease, social determinants) and program (deceased versus live donation) factors. Adult Ontario residents waitlisted for first LT at Toronto General Hospital from November 2012 to May 2019 were reviewed.

Cooperation Between the NRF2 Pathway and Oncogenic β‐catenin During HCC Tumorigenesis

Mathilde Savall, Nadia Senni, Isabelle Lagoutte, Pierre Sohier, Renaud Dentin, Beatrice Romagnolo, Christine Perret, Pascale Bossard – 3 June 2021 – CTNNB1 (catenin beta 1)–mutated hepatocellular carcinomas (HCCs) account for a large proportion of human HCCs. They display high levels of respiratory chain activity. As metabolism and redox balance are closely linked, tumor cells must maintain their redox status during these metabolic alterations. We investigated the redox balance of these HCCs and the feasibility of targeting this balance as an avenue for targeted therapy.

Subscribe to